Clinical Trials Logo

Filter by:
NCT ID: NCT06154902 Active, not recruiting - Multiple Myeloma Clinical Trials

Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel

ABE-DESCART
Start date: July 29, 2022
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in France with relapsed/refractory multiple myeloma (RRMM) who are eligible for treatment with, or have been treated with, idecabtagene vicleucel. This study will use both prospective and retrospective data from the DESCAR-T registry database.

NCT ID: NCT06137170 Active, not recruiting - Clinical trials for Metastatic Colorectal Cancer

A Real-World Study to Learn More About the Order of Different Treatments and Their Effects in People With Metastatic Colorectal Cancer Receiving Their Third and Fourth Line of Treatment

RegoSeq
Start date: March 1, 2024
Phase:
Study type: Observational

This is an observational study in which data already collected from people with metastatic colorectal cancer will be studied. Metastatic colorectal cancer (mCRC) is a cancer of the colon (large bowel) or the rectum (lowest part of the bowel just before the anus). Cancer is considered metastatic if it spreads to other parts of the body. The study drug, regorafenib, is already approved for doctors to prescribe to people with mCRC. It is an anti-cancer drug that blocks several proteins, called enzymes, which are involved in the growth of cancer. Other approved treatments for mCRC include TAS and bevacizumab. The combination of the anti-cancer drugs trifluridine and tipiracil is called TAS. Both TAS and bevacizumab prevent cancer cells from growing and multiplying. Some studies have shown that people with mCRC who took TAS along with bevacizumab, lived longer than when TAS was taken alone. This may be especially beneficial for patients who have tried other treatments before. However, there is limited knowledge about how and in which order these drugs are given. To better understand the impact of the order of taking regorafenib and TAS, with or without bevacizumab, more knowledge is needed about how well these treatments work in people with mCRC in European countries. The main purpose of this study is to learn more about the effects of treatment in people with mCRC who have already received regorafenib and TAS, with or without bevacizumab, one after the other (also called sequential treatment) in a different order. To do this, researchers will collect the following information: - how long participants received sequential treatment for mCRC - number of participants receiving further treatment for mCRC after the sequential treatment - number and type of further treatments for mCRC - how long did participants live (also called overall survival). The data will come from the participants' information stored in health records from 4 centers in 3 European countries including France, Italy, and Spain. The data will be from people with mCRC who started sequential treatment between January 2013 and December 2022 or until the most recent date that allows researchers to assess the participants' health for at least 3 months. In this study, only available data from routine care are collected. No visits or tests will be required as part of this study.

NCT ID: NCT06128382 Active, not recruiting - Coronavirus Clinical Trials

First-in-human Study to Evaluate the Safety and Immunogenicity of Three Dose Levels of the OVX033 Coronavirus Vaccine Candidate in Healthy Volunteers

Start date: January 8, 2024
Phase: Phase 1
Study type: Interventional

This first-in-human clinical trial is designed to evaluate the safety and immunogenicity of one administration of OVX033 coronavirus vaccine at different dose levels (100µg, 250µg and 500µg)

NCT ID: NCT06110182 Active, not recruiting - Clinical trials for Leukemia, Lymphoblastic

Evaluation of the Advantage in the Use of Enteral Nutrition in Children Treated for Acute Lymphoblastic Leukemia

Start date: October 1, 2023
Phase:
Study type: Observational

This is a multicenter retrospective study (Reims and Nancy), with data collection over 12 years from 01/01/2010 to 12/31/2022 Patients included are children diagnosed with acute lymphoblastic leukemia between 2010 and 2021 in the 2 centers. Patients will be categorized into 3 groups: - No nutritional support - Support by enteral nutrition - Parenteral nutrition support Their nutritional status will be assessed at the end of induction, at 6 months and then at 12 months from diagnosis. The main objective of this study is therefore to compare the nutritional status of children with acute lymphoblastic leukemia depending on whether they received enteral or parenteral nutritional support during their treatment. The secondary objective is to evaluate the occurrence of complications during treatment according to the nutritional support received.

NCT ID: NCT06108609 Active, not recruiting - Clinical trials for Reproducibility, Internal Consistency, Relevance and Discriminatory Performance of the Tests

Validation of the French Version of the Hearing Aid Benefit Measurement COSI and IOI-HA Questionnaires

AUDI-FR
Start date: October 25, 2023
Phase:
Study type: Observational

Estimating patient satisfaction is essential in modern day-to-day medical practice. This is particularly true in the field of audiology where evaluating the benefit of patients' devices makes it possible to improve settings and increase patient satisfaction and therefore compliance. Questionnaires measuring hearing aid benefit such as the IOI-HA (International Outcome Inventory for Hearing Aids) and the COSI (Client Oriented Scale of Improvement) are used in everyday practice and promote cooperation between researchers by providing comparable data. Unlike other countries, these questionnaires have never been validated in French by psychometric studies. The objective of this study is to validate the translation of the IOI-HA questionnaire already used in the clinic and to adapt the COSI into French and statistically validate its translation.

NCT ID: NCT06101680 Active, not recruiting - Rhabdomyolysis Clinical Trials

RhabdomYolyse in Intensive caRe

RYR
Start date: October 1, 2023
Phase:
Study type: Observational

Analysis of the outcome of patients < 18 years old, treated in an intensive care unit for severe rhabdomyolysis, regardless of etiology (renal failure rate, death rate, organ replacement rate)

NCT ID: NCT06100354 Active, not recruiting - Orthopedic Disorder Clinical Trials

Study of Patient Preferences in Relation to the Fitting of a Personalized and Connected Joint Prosthesis.

FKprefPat
Start date: December 12, 2022
Phase:
Study type: Observational

The goal of this observational study is to learn about patients' preference toward the use of customized and connected prosthesis. The main questions it aims to answer are: - What is the acceptability of new customization and connectivity technologies by patients? - Are they all at the same level of acceptability? Participants will have to answer to a questionnaire of choice.

NCT ID: NCT06095115 Active, not recruiting - Plaque Psoriasis Clinical Trials

A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis

ICONIC-LEAD
Start date: October 12, 2023
Phase: Phase 3
Study type: Interventional

The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.

NCT ID: NCT06076785 Active, not recruiting - Clinical trials for Impaired Visual Acuity

Impact of ODYSight in the Management of patientS With imparairEd Visual acuitY

ODYSSEY
Start date: January 27, 2023
Phase:
Study type: Observational

Previous investigations have demonstrated the agreement between OdySight® and standardised methods in the evaluation of near visual acuity. The app allows for remote monitoring of this parameter with tracking changes. In case of decrease in visual acuity, a notification is sent to both patient and ophthalmologist. The aim of this study is to evaluate the medical relevance of OdySight® features in the management of patients suffering from impaired visual acuity.

NCT ID: NCT06071091 Active, not recruiting - Clinical trials for Acute Ischemic Stroke

Permanent Intracranial Stenting for Acute Ischemic Stroke Related to a Refractory Large Vessel Occlusion

PISTAR
Start date: November 8, 2023
Phase: N/A
Study type: Interventional

Clot extraction failure during mechanical thrombectomy is a major concern in the management of acute ischemic stroke related to large vessel occlusions. Indeed, it can occur in up to 10 to 30% of cases and, therefore, is associated with a very poor prognosis. These refractory occlusions frequently occur when an underlying intracranial atherosclerotic disease is present. Thus, one of the most promising rescue technique consists of placing a permanent intracranial stent, under dual antiplatelet therapy over the target refractory occlusion. This strategy is well studied in coronary occlusions where the atheroscotic mechanism is highly prevalent. However, as the ischemiated brain is at much higher risk of hemorrhagic complications, such strategy entails a greater risk. This raises the question of whether such risk is worth the reward of obtaining reperfusion. The investigators designed this randomized study in order to evaluate whether a strategy combining rescue pemanent intracranial stenting with the best medical treatment is superior to the best medical treatment alone in acute refractory large vessel occlusions.